Who is sponsoring NCT05320250?

NCT05320250 is sponsored by Fondazione Don Carlo Gnocchi Onlus.

What drugs are being tested in NCT05320250?

Interventions in NCT05320250: Single saliva collection, Saliva collection, longitudinal.

What condition does NCT05320250 study?

NCT05320250 studies Parkinson's Disease and Parkinsonism.

Is NCT05320250 still recruiting?

NCT05320250 is currently completed. Last updated 13 January 2025.

Last reviewed 2025-01-13 · How we verify

NCT05320250: RaSPiD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Saliva and Extracellular Vesicles for Parkinson's Disease

Completed Last updated 13 January 2025

What this trial tests

trial testing Single saliva collection in Parkinson's Disease and Parkinsonism in 165 participants. Completed in 31 December 2024.

Timeline

15 December 2021

Primary endpoint
31 October 2024

31 December 2024

Quick facts

Lead sponsor	Fondazione Don Carlo Gnocchi Onlus
Status	Completed
Study type	OBSERVATIONAL
Enrollment	165
Start date	15 December 2021
Primary completion	31 October 2024
Estimated completion	31 December 2024
Sites	4 locations across Italy

Drugs / interventions tested

Single saliva collection
Saliva collection, longitudinal

Conditions studied

Parkinson's Disease and Parkinsonism — all drugs for Parkinson's Disease and Parkinsonism →

Sponsor

Fondazione Don Carlo Gnocchi Onlus — full company profile →

Who can join

Adults 50 to 85, any sex, with Parkinson's Disease and Parkinsonism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Rehabilitation is crucial in the treatment of people with Parkinson's disease (PD) as it can ameliorate motor and non-motor impairments, improving their clinical profile and quality of life. Considering the complex biological processes occurring in PD brain, the identification of accessible and measurable biomarkers to monitor the events induced by intensive rehabilitation would help in i)testing rehabilitation effectiveness, ii)improving the design of clinical trials and iii)personalizing the rehabilitation strategies by the prediction of patients' responsiveness. The objective of this project is the validation of Raman analysis of saliva and salivary extracellular vesicles (EV) for the differential diagnosis of Parkinson's disease (PD) and atypical Parkinsonism. The proposed diagnostic method can be integrated in the preliminary assessment and monitoring of the patient by providing a quickly and repeatable measurable biomarker. In the end, this will bring tothe personalization of the rehabilitation path and provide an indication on the outcome of the rehabilitation treatment.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The Emerging Role of Raman Spectroscopy as an Omics Approach for Metabolic Profiling and Biomarker Detection toward Precision Medicine.
Cutshaw G, Uthaman S, Hassan N, Kothadiya S, et al · · 2023 · cited 95× · PMID 37318957 · DOI 10.1021/acs.chemrev.2c00897
Engineered EVs designed to target diseases of the CNS.
Nieland L, Mahjoum S, Grandell E, Breyne K, et al · · 2023 · cited 46× · PMID 36907561 · DOI 10.1016/j.jconrel.2023.03.009
Emerging Role of Extracellular Vesicles as Biomarkers in Neurodegenerative Diseases and Their Clinical and Therapeutic Potential in Central Nervous System Pathologies.
Malaguarnera M, Cabrera-Pastor A. · · 2024 · cited 30× · PMID 39337560 · DOI 10.3390/ijms251810068
Dual role of brain-derived extracellular vesicles in dementia-related neurodegenerative disorders: cargo of disease spreading signals and diagnostic-therapeutic molecules.
Natale F, Fusco S, Grassi C. · · 2022 · cited 29× · PMID 36437458 · DOI 10.1186/s40035-022-00326-w
Extracellular Vesicles in the Central Nervous System: A Novel Mechanism of Neuronal Cell Communication.
Filannino FM, Panaro MA, Benameur T, Pizzolorusso I, et al · · 2024 · cited 27× · PMID 38338906 · DOI 10.3390/ijms25031629
Extracellular vesicles: biological mechanisms and emerging therapeutic opportunities in neurodegenerative diseases.
Wang L, Zhang X, Yang Z, Wang B, et al · · 2024 · cited 26× · PMID 39643909 · DOI 10.1186/s40035-024-00453-6
Extracellular Vesicles as Biomarkers for Parkinson's Disease: How Far from Clinical Translation?
Gualerzi A, Picciolini S, Bedoni M, Guerini FR, et al · · 2024 · cited 17× · PMID 38256215 · DOI 10.3390/ijms25021136
Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions.
Choi HK, Chen M, Goldston LL, Lee KB. · · 2024 · cited 11× · PMID 38739358 · DOI 10.1186/s40580-024-00426-5

Verify or expand the search:

Other recruiting trials for Parkinson's Disease and Parkinsonism

Currently open trials in the same condition.

NCT07153692 — Clinical Efficacy and Mechanism of tDCS for Dysphagia in PD · NA · recruiting
NCT06914466 — Neural Mechanisms and Clinical Applications of DBS for Modulating Sleep Dysregulation in PD · recruiting
NCT06400017 — Mechanism and Application of DBS in the Treatment of PD · NA · recruiting
NCT06174948 — The Use of the CUE1/CUE1+ in People With Parkinson's Disease and Related Disorders · NA · recruiting
NCT05934747 — Aim 3 Particle Swarm Optimization PIGD · NA · recruiting

Other Fondazione Don Carlo Gnocchi Onlus trials

Trials by the same sponsor.

NCT07252856 — Transcultural Digital Solutions in Phase III Cardiac Rehabilitation · NA · not yet recruiting
NCT07290218 — Tridimensional Robotic Assessment of Neglect in Brain Injured Patients · not yet recruiting
NCT07064226 — Validation of a Digital Intervention to Rehabilitate Cognitive Resources · NA · recruiting
NCT07130929 — Functional Electrical Stimulation to Treat Critical Neuromyopathy After Severe Stroke: a Pilot Study. · NA · recruiting
NCT07159854 — Telerehabilitation in Central and Peripheral Neurological Sequelae From Chemotherapy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05320250 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondazione Don Carlo Gnocchi Onlus
Last refreshed: 13 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05320250.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing